Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? by Schaefer, N G et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2004
Non-Hodgkin lymphoma and Hodgkin disease: coregistered
FDG PET and CT at staging and restaging--do we need
contrast-enhanced CT?
Schaefer, N G; Hany, T F; Taverna, C; Seifert, B; Stumpe, K D M; von Schulthess, G
K; Goerres, G W
Schaefer, N G; Hany, T F; Taverna, C; Seifert, B; Stumpe, K D M; von Schulthess, G K; Goerres, G W (2004).
Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need
contrast-enhanced CT? Radiology, 232(3):823-829.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Radiology 2004, 232(3):823-829.
Schaefer, N G; Hany, T F; Taverna, C; Seifert, B; Stumpe, K D M; von Schulthess, G K; Goerres, G W (2004).
Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need
contrast-enhanced CT? Radiology, 232(3):823-829.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Radiology 2004, 232(3):823-829.
Non-Hodgkin lymphoma and Hodgkin disease: coregistered
FDG PET and CT at staging and restaging--do we need
contrast-enhanced CT?
Abstract
PURPOSE: To retrospectively compare diagnostic value of coregistered fluorine 18 fluorodeoxyglucose
positron emission tomographic (PET) and computed tomographic (CT) scans obtained with low-dose
nonenhanced CT (PET/CT) with those routinely obtained with contrast material-enhanced CT for
staging and restaging of disease in patients with Hodgkin disease or high-grade non-Hodgkin
lymphoma. MATERIALS AND METHODS: Sixty patients (mean age, 39.6 years +/- 17.1 [standard
deviation]) with Hodgkin disease (n = 42) or high-grade non-Hodgkin lymphoma (n = 18) were included
in this retrospective study. All patients underwent PET/CT and contrast-enhanced CT within a
maximum of 24 days (mean, 9.1 days +/- 7.0) of each other for staging (n = 19) or first follow-up
examination (n = 41). Findings were extracted from original written reports (PET/CT, contrast-enhanced
CT) and compared with findings of reference standard, which included biopsy or follow-up with
clinical, laboratory, or other imaging findings. For statistical analysis, sensitivity and specificity were
calculated with findings of the reference standard. Agreement of both methods was determined with
Cohen kappa and McNemar tests on a per-patient basis. RESULTS: For evaluation of lymph node
involvement, sensitivity of PET/CT and contrast-enhanced CT was 94% and 88%, and specificity was
100% and 86%, respectively. For evaluation of organ involvement, sensitivity of PET/CT and
contrast-enhanced CT was 88% and 50%, and specificity was 100% and 90%, respectively. Agreement
of both methods was excellent (kappa = 0.84) for assignment of lymph node involvement but only fair
(kappa = 0.50) for extranodal disease. A difference with P <.05 (McNemar test) was considered
significant in regard to exclusion of disease with PET/CT, compared with contrast-enhanced CT.
CONCLUSION: PET/CT performed with nonenhanced CT is more sensitive and specific than is
contrast-enhanced CT for evaluation of lymph node and organ involvement, especially regarding
exclusion of disease, in patients with Hodgkin disease and high-grade non-Hodgkin lymphoma.
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Non-Hodgkin Lymphoma and
Hodgkin Disease: Coregistered
FDG PET and CT at Staging
and Restaging—Do We Need
Contrast-enhanced CT?1
PURPOSE: To retrospectively compare diagnostic value of coregistered fluorine 18
fluorodeoxyglucose positron emission tomographic (PET) and computed tomo-
graphic (CT) scans obtained with low-dose nonenhanced CT (PET/CT) with those
routinely obtained with contrast material–enhanced CT for staging and restaging of
disease in patients with Hodgkin disease or high-grade non-Hodgkin lymphoma.
MATERIALS AND METHODS: Sixty patients (mean age, 39.6 years  17.1
[standard deviation]) with Hodgkin disease (n  42) or high-grade non-Hodgkin
lymphoma (n  18) were included in this retrospective study. All patients under-
went PET/CT and contrast-enhanced CT within a maximum of 24 days (mean, 9.1
days  7.0) of each other for staging (n  19) or first follow-up examination (n 
41). Findings were extracted from original written reports (PET/CT, contrast-en-
hanced CT) and compared with findings of reference standard, which included
biopsy or follow-up with clinical, laboratory, or other imaging findings. For statistical
analysis, sensitivity and specificity were calculated with findings of the reference
standard. Agreement of both methods was determined with Cohen  and McNemar
tests on a per-patient basis.
RESULTS: For evaluation of lymph node involvement, sensitivity of PET/CT and
contrast-enhanced CT was 94% and 88%, and specificity was 100% and 86%,
respectively. For evaluation of organ involvement, sensitivity of PET/CT and con-
trast-enhanced CT was 88% and 50%, and specificity was 100% and 90%, respec-
tively. Agreement of both methods was excellent (  0.84) for assignment of
lymph node involvement but only fair (  0.50) for extranodal disease. A difference
with P  .05 (McNemar test) was considered significant in regard to exclusion of
disease with PET/CT, compared with contrast-enhanced CT.
CONCLUSION: PET/CT performed with nonenhanced CT is more sensitive and
specific than is contrast-enhanced CT for evaluation of lymph node and organ
involvement, especially regarding exclusion of disease, in patients with Hodgkin
disease and high-grade non-Hodgkin lymphoma.
© RSNA, 2004
Positron emission tomography (PET) with fluorine 18 fluorodeoxyglucose (FDG) is used for
staging and follow-up examinations in patients with Hodgkin disease and non-Hodgkin
lymphoma. In comparison with morphologic imaging with contrast material–enhanced
computed tomography (CT), metabolic imaging with FDG PET showed a higher specificity
in the staging of disease (1–3). Small lesions, however, may be missed at PET when FDG
uptake is low. The addition of metabolic imaging can have a great effect on treatment in
patients with a residual mass at posttreatment evaluation (4). Therefore, FDG PET mainly
has been performed in addition to contrast-enhanced CT for staging and follow-up
examinations.
With the recent introduction of in-line FDG PET with coregistered nonenhanced CT
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(PET/CT) scanners, a combined method
of metabolic and morphologic imaging is
available. PET and CT data can be ac-
quired in the same imaging session, with-
out the need to change the patient posi-
tion between scanning with one modality
and the other, to obtain coregistered im-
ages. Routinely, nonenhanced low-dose
CT is used for attenuation correction, as
well as image coregistration (5).
The aim of this study was to retrospec-
tively compare the diagnostic value of
coregistered PET/CT scans obtained with
low-dose nonenhanced CT with those
routinely obtained with contrast-en-
hanced CT for staging and restaging of
disease in patients with Hodgkin disease
or high-grade non-Hodgkin lymphoma.
MATERIALS AND METHODS
Patients
Between May 2001 and October 2002,
60 patients (37 men, 23 women; mean
age, 39.6 years  17.1 [standard devia-
tion]) who were examined in our PET/CT
institute at Department of Nuclear Med-
icine, University Hospital Zurich, Zurich,
Switzerland, were included in this retro-
spective analysis. Forty-two had histolog-
ically proved Hodgkin disease; of this
number, 27 were men (mean age, 37.3
years  14.3) and 15 were women (mean
age, 33.1 years  14.6). Eighteen had
non-Hodgkin lymphoma; of this num-
ber, 10 were men (mean age, 46.2 years
23.8) and eight were women (mean age,
51.3 years  14.3). In Table 1, patient
characteristics are listed. We consecu-
tively included all patients who under-
went contrast-enhanced CT and PET/CT
within 24 days apart of each other with-
out treatment between examinations in
this time period. For staging purposes,
PET/CT and contrast-enhanced CT were
performed in 19 patients (11 with
Hodgkin disease and eight with non-
Hodgkin lymphoma). In 41 patients eval-
uated for restaging (31 with Hodgkin
disease and 10 with non-Hodgkin lym-
phoma), PET/CT and contrast-enhanced
CT were performed after at least two cy-
cles of chemotherapy or after given times
(3, 6, or 12 months) after the completion
of therapy. The records of all patients
were reviewed (N.G.S.) in accordance
with the ethical guidelines of the hospi-
tal institutional review board after signed
written informed consent was obtained.
Imaging
All data were acquired with a com-
bined PET/CT in-line system (Discovery
LS; GE Medical Systems, Waukesha, Wis).
This dedicated system integrates a PET
scanner (Advance NXi; GE Medical Sys-
tems) with a multisection helical CT
scanner (LightSpeed Plus; GE Medical
Systems) and permits the acquisition of
coregistered CT and PET images in one
session.
Patients fasted for at least 4 hours prior
to scanning, which started 40–60 min-
utes after the injection of a standard dose
of 370 MBq of FDG. In addition, an oral
CT contrast agent (Micropaque Scanner;
Guerbet, Aulnay-sous-bois, France) was
administered, starting 15 minutes before
the injection of FDG (6). Patients were
examined in the supine position. No
intravenous contrast agent was adminis-
tered. An oral contrast agent was admin-
istered for all CT and PET/CT examina-
tions. Initially, starting at the level of the
head, the CT scans were acquired with
the following parameters: 80 mA, 140 kV,
0.5-second tube rotation, 4.25-mm sec-
tion thickness, 867-mm scan length, and
22.5-second data acquisition time. The
CT scans were acquired during breath
hold with the normal expiration posi-
tion, and scanning included the area
from the head to the pelvic floor.
Immediately following CT, a PET emis-
sion scan was acquired, with an acquisi-
tion time of 4 minutes for the emission
scan per cradle position and a one-sec-
tion overlap. Acquisition of scans in six
cradle positions from the pelvic floor to
the head resulted in an acquisition time
of approximately 24 minutes. The CT
data were used for attenuation correc-
tion, and images were reconstructed by
using a standard iterative algorithm (or-
dered subset expectation maximization).
The acquired images were viewed with
software that provided multiplanar refor-
matted images of PET, CT, and fused data
with linked cursors (eNtegra 3.0215; GE
Medical Systems).
Contrast-enhanced CT was performed
in different hospitals. All were equipped
with helical CT scanners: a single-section
unit (Sele; Picker/Elscint, Hamburg, Ger-
many) and two multisection units (Emo-
tion Dual Slice CT, Siemens, Erlangen,
Germany; Somatom Volume Zoom, Sie-
mens). The CT scanners were either sin-
gle- or multisection scanners, and imag-
ing of the neck, thorax, abdomen, and
pelvis was performed according to the
guidelines of the American College of Ra-
diology, with acquisition of contiguous
sections of 5-mm thickness. In all pa-
tients, data acquisition included the
same anatomic regions from the neck to
the pelvic floor as were included in
PET/CT scans. All contrast-enhanced CT
examinations were performed with an in-
travenous injection of 120–200 mL of
contrast medium. All CT images were dis-
played as transverse sections.
PET/CT and contrast-enhanced CT
data were acquired within a maximum of
24 days (mean, 9.1 days  7.0) of each
other. The mean clinical follow-up for
the confirmation of findings at PET/CT or
contrast-enhanced CT that were negative
was 9.3 months  2.5.
Imaging and Pathologic Finding
Analysis
The information about possible or ev-
ident pathologic findings described in
original written reports of PET/CT and
contrast-enhanced CT results was used to
perform statistical analysis (N.G.S., B.S.).
All pathologic findings as reported with
PET/CT were directly compared with
findings reported with contrast-en-
hanced CT for the assignment of the an-
atomic localization of lymph node in-
volvement and the identification of
organ infiltration by two readers (N.G.S.,
G.W.G.). Only when discrepant findings
between PET/CT and contrast-enhanced
CT were reported were the images viewed
again by two readers in consensus. Both
readers were board-certified nuclear med-
icine physicians and radiologists (T.F.H.,
G.W.G.) with more than 2 years of expe-
rience in interpretation of PET/CT scans
and 8 years of experience in interpreta-
tion of contrast-enhanced CT scans. This
allowed assessment if a lesion was missed
with one imaging method.
All pathologic findings described in
the original written reports were ranked
to assign the probability of lymphoma
involvement of a given lesion on PET/CT
and contrast-enhanced CT scans, sepa-
rately, with the following grading scale: 0
(no lymphoma), 1 (possible lymphoma),
or 2 (evident lymphoma involvement).
In addition, a consensus was reached
about whether a lesion corresponded to
lymph node or organ involvement due to
lymphoma. The findings of PET/CT and
contrast-enhanced CT were compared
with histologic findings, if available (re-
staging in seven of 41 patients, staging in
13 of 19 patients). Clinical follow-up was
investigated in all 60 patients at a mean
of 9.3 months  2.5 after imaging
(N.G.S.). The standard of reference was
preferably biopsy, if available, or follow-
up, which included clinical, laboratory,
or other imaging (plain radiography,
magnetic resonance [MR] imaging, bone
scintigraphy) findings.
824  Radiology  September 2004 Schaefer et al
R
a
d
io
lo
gy
In regard to change in treatment, ret-
rospective analysis of the patient’s
chart was performed to determine
whether the treatment was based on
PET/CT or contrast-enhanced CT find-
ings. In addition, the treating oncolo-
gist (N.G.S.) was contacted to deter-
mine whether treatment decisions were
based on contrast-enhanced CT or
PET/CT findings.
Statistical Analysis
Sensitivity and specificity were calcu-
lated on the basis of the true-positive and
true-negative findings as described in the
TABLE 1
Patient Characteristics
Stage Sex/Age (y) Type of Disease Primary Site of Disease
IA F/19 HD, nodular sclerosis Mediastinal lymph nodes
IA F/31 HD, nodular sclerosis Mediastinal lymph nodes
IA F/76 HD, nodular sclerosis Axillary lymph nodes
IB F/44 HD, nodular sclerosis Mediastinal lymph nodes
IB F/26 HD, nodular sclerosis Mediastinal lymph nodes
IIA F/27 HD, nodular sclerosis Paratracheal, mediastinal lymph nodes
IIA F/28 HD, nodular sclerosis Subcarinal, paraaortal lymph nodes
IIA F/27 HD, nodular sclerosis Mediastinal, pretracheal lymph nodes
IIA F/31 HD, nodular sclerosis Mediastinal, axillary lymph nodes
IIA F/37 HD, nodular sclerosis Cervical, mediastinal lymph nodes
IIAE F/20 HD, nodular sclerosis Lung infiltration, mediastinal lymph nodes
IIB F/41 HD, nodular sclerosis Cervical, supraclavicular, mediastinal lymph nodes
IIIB F/45 HD, nodular sclerosis Mediastinal, supraclavicular, paratracheal lymph nodes; splenic hilum
IVBE F/17 HD, nodular sclerosis Cervical, supraclavicular, mediastinal lymph nodes; bone infiltration
IVBES F/28 HD, nodular sclerosis Supraclavicular, infraclavicular, axillary, iliac lymph nodes; spleen and bone infiltration
IA M/64 HD, mixed cell type Cervical lymph nodes
IIA M/46 HD, mixed cell type Pharyngeal, cervical lymph nodes
IIA M/42 HD, mixed cell type Mediastinal, axillary lymph nodes
IIA M/25 HD, mixed cell type Mediastinal, cervical lymph nodes
IIB M/35 HD, mixed cell type Cervical, supraclavicular, mediastinal lymph nodes
IIBE M/22 HD, mixed cell type Mediastinal, supraclavicular, peribronchial lymph nodes; lung infiltration
IB M/59 HD, nodular sclerosis Retroperitoneal lymph nodes
IB M/31 HD, nodular sclerosis Mediastinal lymph nodes
IB M/66 HD, nodular sclerosis Iliac lymph nodes
IIA M/23 HD, nodular sclerosis Mediastinal, cervical lymph nodes
IIA M/24 HD, nodular sclerosis Mediastinal, cervical lymph nodes
IIA M/67 HD, nodular sclerosis Cervical, mediastinal lymph nodes
IIA M/35 HD, nodular sclerosis Axillary, mediastinal lymph nodes
IIA M/27 HD, nodular sclerosis Mediastinal, cervical lymph nodes
IIA M/43 HD, nodular sclerosis Supraclavicular, mediastinal lymph nodes
IIA M/20 HD, nodular sclerosis Cervical, axillary, mediastinal lymph nodes
IIA M/34 HD, nodular sclerosis Iliac, inguinal lymph nodes
IIA M/23 HD, nodular sclerosis Supraclavicular, peribronchial lymph nodes
IIB M/37 HD, nodular sclerosis Cervical, paratracheal lymph nodes
IIB M/42 HD, nodular sclerosis Mediastinal, supraclavicular, paratracheal lymph nodes
IIBE M/24 HD, nodular sclerosis Mediastinal lymph nodes, lung infiltration
IIIA M/42 HD, nodular sclerosis Mediastinal lymph nodes, retroperitoneal lymph nodes
IIIA M/49 HD, nodular sclerosis Paraaortal, aortopulmonary, pretracheal lymph nodes
IIIAS M/47 HD, nodular sclerosis Cervical, supraclavicular, mediastinal, iliac lymph nodes; retroperitoneal lymph nodes
IIIBS M/22 HD, nodular sclerosis Spleen infiltration; mediastinal, axillary, supraclavicular lymph nodes
IIIBS M/25 HD, nodular sclerosis Spleen infiltration; mediastinal, supraclavicular lymph nodes
IIIBS M/32 HD, nodular sclerosis Cervical, supraclavicular, mediastinal lymph nodes; retroperitoneal lymph nodes;
spleen infiltration
IAE F/52 NHL, B-cell lymphoma Lung infiltration
IB F/61 NHL, B-cell lymphoma Mediastinal lymph nodes
IB F/34 NHL, B-cell lymphoma Mediastinal lymph nodes
IE F/69 NHL, B-cell lymphoma Bone infiltration
IIA F/48 NHL, B-cell lymphoma Mediastinal lymph nodes
IIA F/37 NHL, B-cell lymphoma Mediastinal lymph nodes
IVB F/70 NHL, B-cell lymphoma Cervical, supraclavicular, axillary, mediastinal, paraaortal, iliac, inguinal lymph nodes
IVBES F/39 NHL, B-cell lymphoma Liver, spleen infiltration; bone marrow
IA M/54 NHL, B-cell lymphoma Cervical lymph nodes
IAE M/81 NHL, B-cell lymphoma Duodenal infiltration
IB M/17 NHL, B-cell lymphoma Mediastinal lymph nodes
IB M/77 NHL, B-cell lymphoma Mediastinal lymph nodes
IIA M/17 NHL, B-cell lymphoma Mediastinal lymph nodes
IIAS M/49 NHL, B-cell lymphoma Inguinal, iliac lymph nodes; spleen infiltration
IIB M/61 NHL, B-cell lymphoma Pharyngeal, cervical lymph nodes
IVA M/52 NHL, B-cell lymphoma Mesenteric lymph nodes
IVA M/17 NHL, B-cell lymphoma Lung infiltration, mesenteric lymph nodes
IVBS M/37 NHL, T-cell lymphoma Cervical, axillary, paraaortal, iliac lymph nodes; spleen infiltration
Note.—HD  Hodgkin disease, NHL  non-Hodgkin lymphoma.
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same anatomic region (N.G.S. and B.S.).
Statistical analysis was performed with
software (StatView, version 5.0.1; SAS In-
stitute, Cary, NC). The agreement of
PET/CT and contrast-enhanced CT find-
ings was assessed separately for lymph
node and organ involvement with the 
statistic. The agreement was determined,
with  values as follows: 0–0.20, very
poor; 0.21–0.40, poor; 0.41–0.60, fair;
0.61–0.80, good; and 0.81–1.00, excel-
lent.
The following regions were used for
the anatomic assignment of lymph node
involvement to measure the agreement
between the methods: neck, mediasti-
num, axilla, abdomen, retroperitoneal
space, and groin. Organ involvement was
assessed for the lung, liver, spleen, gastro-
intestinal tract, and bone marrow.
To evaluate the difference in probabil-
ity assignment between the two imaging
modalities, we separately analyzed the
data in regard to the standard of refer-
ence (true-positive and true-negative re-
sults according to the standard of refer-
ence). We applied the McNemar test
separately in these two groups, with a
confidence level of 95% (a difference
with P  .05 was considered significant).
Furthermore, the McNemar test accord-
ing to sex (male or female patients) and
histologic findings (Hodgkin disease or
non-Hodgkin lymphoma) was used to
determine a significant difference be-
tween these subgroups (N.G.S., G.W.G.,
B.S.). All tests were performed on a per-
patient basis, and hence, dependency or
clustering did not occur. With the McNe-
mar test, the P value after Bonferroni cor-
rection was calculated as .05/6  .008.
RESULTS
Lymph Node Involvement
At initial staging, all 19 patients in the
staging group had evidence of Hodgkin
disease or non-Hodgkin lymphoma at
one or more lymph node stations, and
this evidence was correctly demonstrated
with both imaging modalities. In four of
these 19 patients, PET/CT depicted ad-
ditional nodal involvement, which was
not detected at contrast-enhanced CT.
Contrast-enhanced CT did not depict
nodal involvement that was not seen at
PET/CT.
In a total of 41 patients who under-
went imaging with both modalities for
restaging, lymph node involvement
was found in 11 patients with PET/CT
and in 13 patients with contrast-en-
hanced CT (Table 2). Concordant
lymph node involvement was reported
in seven patients. In four patients,
PET/CT depicted additional nodal in-
volvement. In two of these patients, in-
creased FDG uptake was histologically
confirmed as nodal involvement. In a
third patient, PET/CT depicted a suspi-
cious lymph node that was not histo-
logically or cytologically confirmed. In
the fourth patient, a mesenteric bulk
considered as stable disease at contrast-
enhanced CT (1-year follow-up after
the completion of chemotherapy) re-
vealed increased FDG uptake at PET/CT.
Two false-negative lesions were found
at PET/CT: First, a paraaortic lymph
node shown on contrast-enhanced CT
images revealed no FDG uptake and was
missed on the nonenhanced CT image
at PET/CT. Second, subcarinal lymph
node involvement with Hodgkin dis-
ease in a 3.8-cm-diameter enlarged
lymph node was not depicted on
PET/CT images but was identified on
contrast-enhanced CT scans and was
proved at biopsy. In 24 patients, no
nodal involvement was detected with
both imaging modalities. In an addi-
tional four patients, contrast-enhanced
CT depicted lymph nodes suspicious for
lymphoma involvement. All patients
remained without further evidence of
recurrent lymphoma during clinical
follow-up, and findings were consid-
ered false-positive.
The sensitivity and specificity for
lymph node involvement on a per-pa-
tient basis was 94% (30 of 32) and 100%
(28 of 28) for PET/CT and 88% (28 of 32)
and 86% (24 of 28) for contrast-en-
hanced CT. The McNemar test for the
probability assignment of suspicious le-
sions revealed no significant difference
between PET/CT and contrast-enhanced
CT, with P  .07 for exclusion of patho-
logic lymph node involvement and P 
.37 for true-positive involvement of
lymph nodes.
Organ Involvement
In 15 of 19 patients who underwent
PET/CT and contrast-enhanced CT for
staging purposes, no organ involvement
was reported (Figure). In three patients,
extranodal disease was reported at
PET/CT (one patient each had bone inva-
sion, spleen infiltration, and a combina-
tion of both). Bone involvement was
confirmed at bone scintigraphy, MR im-
aging, and additional radiography. This
confirmation led to an upgrading of the
stage of the disease. The spleen involve-
ment was confirmed after 10 months at
follow-up PET/CT, which showed pro-
gression of the disease. In all three pa-
tients, the PET/CT findings were consid-
ered to be true-positive (Table 3). In one
patient, at contrast-enhanced CT for
staging, findings indicated additional
small-bowel involvement. These findings
led to an adaptation of treatment, and
thus, findings were considered true-posi-
tive at contrast-enhanced CT and corre-
spondingly false-negative at PET/CT. No
false-positive findings were reported with
PET/CT and contrast-enhanced CT for
staging (Table 3).
At restaging examinations, involve-
ment of one or more organs was reported
at PET/CT in four patients and at con-
trast-enhanced CT in eight patients. A
concordance for the presence of organ
involvement was reported with both
methods in three patients. At PET/CT,
additional organ involvement was iden-
tified in two patients. In one patient,
spleen infiltration was histologically con-
firmed, with additional recurrence in a
retroperitoneal lymph node and liver in-
volvement; this finding was described al-
ready at PET/CT and contrast-enhanced
CT. This finding therefore did not change
the results on a per-patient basis. In the
second patient, infiltration of the duode-
nal loop was found with PET/CT because
of highly increased FDG uptake after
chemotherapy. The corresponding con-
TABLE 2
Results of Lymph Node Evaluation on a Per-Patient Basis
Finding
Staging Restaging
PET/CT CT* PET/CT CT*
True-positive 19 19 11 9
False-positive 0 0 0 4
True-negative 0 0 28 24
False-negative 0 0 2 4
Note.—Data are numbers of patients.
* With contrast enhancement.
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trast-enhanced CT scan showed no wall
thickening or other signs of bowel in-
volvement with lymphoma. This finding
was not histologically confirmed but
nevertheless invoked resumption of che-
motherapy. Therefore, the finding was
considered true-positive at PET/CT and
false-negative at contrast-enhanced CT
(Table 3). In 32 patients, no organ in-
volvement was found at both contrast-
enhanced CT and PET/CT.
In five patients, seven extranodal le-
sions were depicted with contrast-en-
hanced CT that were not depicted at PET/
CT. In four patients, pathologic lung
infiltration was found with contrast-en-
hanced CT, and in one patient, involve-
ment of the liver, spleen, and bone mar-
row was described. These lung lesions,
usually described as patchy areas of opac-
ity, were considered to correspond to
lymphoma. However, at clinical evalua-
tion with follow-up contrast-enhanced
CT, findings were normal in all four pa-
tients, thus confirming the results with
true-negative PET/CT scans. In the pa-
tient with liver, spleen, and bone marrow
involvement depicted with contrast-en-
hanced CT, findings at PET/CT were neg-
ative and clinical follow-up with con-
trast-enhanced CT after 4 months
revealed no pathologic findings or clini-
cal signs of recurrence. In these five pa-
tients with erroneously suspected extra-
nodal lymphoma at contrast-enhanced
TABLE 3
Results of Organ Evaluation on a Per-Patient Basis
Finding
Staging Restaging
PET/CT CT* PET/CT CT*
True-positive 3 1 4 3
False-positive 0 0 0 5
True-negative 15 15 37 32
False-negative 1 3 0 1
Note.—Data are numbers of patients.
* With contrast enhancement.
(a–c) PET/CT images in 17-year-old adolescent girl with swollen supraclavicular lymph nodes. Contrast-enhanced CT scan acquired 2 days earlier
revealed presence of enlarged lymph nodes in neck, thorax, and abdomen but did not identify osseous involvement. (a) Coronal maximum
intensity projection image shows intense uptake bilaterally in enlarged lymph nodes at the neck/supraclavicular level (upper arrow) and uptake in
mediastinum (lower arrow). There is no increased FDG uptake at abdominal lymph node sites and there is a normal appearance of the upper
abdominal organs, especially the spleen. In contrast, there is an asymmetric appearance at the ischial tuberosity (arrowhead). There is FDG
contamination (*) at the right arm after intravenous tracer injection. (b) Scans show extensive involvement of lymph nodes in the mediastinum,
with highly increased FDG uptake (arrowheads). Top: Transverse CT scan. Middle: Transverse PET scan. Bottom: Coregistered PET/CT image.
(c) Transverse scans obtained at level of the pelvic floor reveal presence of a bone metastasis at the ischial tuberosity (arrow). This lesion has a
sclerotic margin and was missed on the conventional contrast-enhanced CT image. Top: Transverse CT scan. Middle: PET scan. Bottom:
Coregistered PET/CT image.
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CT, the treatment did not change, and all
contrast-enhanced CT findings were con-
sidered false-positive (Table 3).
The sensitivity and specificity for ex-
tranodal involvement on a per-patient
basis were 88% (seven of eight) and 100%
(52 of 52) for PET/CT and 50% (four of
eight) and 90% (47 of 52) for contrast-
enhanced CT, respectively. The McNe-
mar test for the probability assignment of
suspicious lesions revealed no significant
difference between both imaging meth-
ods, with P  .07 for the exclusion of
pathologic organ involvement and P 
.37 for the assignment of organ involve-
ment with Hodgkin disease and high-
grade non-Hodgkin lymphoma.
On the basis of findings at PET/CT for
staging, treatment was changed in three
(16%) patients, and on the basis of con-
trast-enhanced CT findings, it was
changed in one (5.2%) patient. For the
restaging examinations, PET/CT revealed
additional findings that led to a change
of treatment in six (15%) patients, and
contrast-enhanced CT revealed addi-
tional findings that led to an adaptation
of treatment in one (2.4%) patient.
Overall, the sensitivity and specificity
for lymph node and organ involvement
on a per-patient basis were 93% (37 of 40)
and 100% (80 of 80) for PET/CT and 80%
(32 of 40) and 89% (71 of 80) for con-
trast-enhanced CT, respectively. The Mc-
Nemar test for the comparison of the
probability assignment of suspicious le-
sions between PET/CT and contrast-en-
hanced CT indicated a significant differ-
ence for the exclusion of pathologic
organ or lymph node involvement (P 
.004) and no significant difference for the
assignment of pathologic involvement
(P  .11).
There were no significant differences
in regard to assignment between the im-
aging modalities according to sex (male
patients, P  .58; female patients, P 
1.0) or histologic findings (Hodgkin dis-
ease, P  .42; non-Hodgkin lymphoma,
P  .68).
The  value as a measure for agreement
between PET/CT and contrast-enhanced
CT revealed that the agreement between
the methods was excellent for lymph
node staging and restaging examina-
tions. However, only a poor to fair agree-
ment was found for evaluation of extra-
nodal disease (Table 4).
DISCUSSION
The data of this retrospective study show
that PET/CT with low-dose nonenhanced
CT for coregistration has a superior diag-
nostic value compared with contrast-en-
hanced CT alone for staging and restag-
ing of disease in patients with high-grade
non-Hodgkin lymphoma or Hodgkin dis-
ease.
Currently, contrast-enhanced CT is the
first-line imaging modality in Hodgkin
disease and non-Hodgkin lymphoma,
which allows the detection of morpho-
logic abnormalities such as lymph node
enlargement or changes in contrast en-
hancement that suggest organ manifesta-
tion. However, disease in normal-sized
lymph nodes and in spleen and bone
marrow is less well depicted (7). In sev-
eral studies, the role of FDG PET for pre-
treatment as well as posttreatment eval-
uation of Hodgkin disease and non-
Hodgkin lymphoma has been evaluated
(1–4,8–12). PET imaging with FDG
showed no difference in depiction of
nodal and extranodal disease compared
with conventional morphologic staging
methods (3,10). In addition, reliable as-
sessment of bone marrow disease was
achieved. On the basis of these findings,
we have translated these procedures into
clinical routine procedures, with FDG
PET imaging as an adjunct to morpho-
logic imaging with contrast-enhanced
CT in staging and restaging of lym-
phoma. Correspondingly, a combination
of both methods as a single-step exami-
nation would simplify diagnostic imag-
ing in patients with lymphoma.
In our study, the  statistic revealed
excellent agreement between PET/CT
and contrast-enhanced CT for the delin-
eation of lymph node involvement, inde-
pendent of the purpose of the examina-
tion for staging or restaging. Basically,
pathologic uptake in lymph nodes of any
size was regarded as lymph node involve-
ment in PET/CT images. With coregistra-
tion of PET and CT images, correct local-
ization of uptake is easily achievable even
though only a low-dose nonenhanced
CT scan was used for coregistration.
These findings confirm previous results
from CT studies, which did not reveal
any significant difference in the detec-
tion of mediastinal lymph nodes with
nonenhanced and enhanced CT (13–15).
Several false-positive contrast-en-
hanced CT findings were reported in re-
gard to lymph node involvement at re-
staging examinations. Particularly, the
remaining soft-tissue densities on con-
trast-enhanced CT images that were re-
garded as persistent disease reflect the de-
layed morphologic response to successful
therapy, and follow-up CT scans in these
patients revealed normal results after a
time. In these cases, PET/CT findings
confirmed the absence of active tumor
tissue with delineation of soft-tissue
masses and without evidence of FDG up-
take corresponding to scar tissue. At PET/
CT, no false-positive results in regard to
lymph node involvement were de-
scribed. This is in contrast to findings in
previous reports with descriptions of a
rather high rate of false-positive findings
at PET, since inflammatory lesions may
demonstrate increased FDG uptake (16).
However, the use of coregistered struc-
tural information increases the specificity
of lesion characterization (17).
In contrast, only a fair agreement was
found for the assessment of organ in-
volvement. The main cause for this dis-
agreement could be found in the rather
large number of false-positive findings at
contrast-enhanced CT, when lung opaci-
ties were interpreted as lymphoma. In
four patients, pulmonary involvement
was reported with contrast-enhanced CT
but was considered a false-positive find-
ing, since spontaneous resolution of
these opacities without therapy was seen
at follow-up examinations. Fundamen-
tally important for staging is the detec-
tion of bone marrow involvement, which
was described in three patients. In two
patients, this involvement was seen ex-
clusively on PET/CT images and was con-
firmed with additional imaging. In con-
trast, at contrast-enhanced CT, bone
infiltration was incorrectly reported in
one patient. This confirms the limita-
tions of contrast-enhanced CT to identify
limited skeletal involvement (7).
On a per-patient basis, overall perfor-
TABLE 4
Agreement between Methods
Involvement Staging Restaging Total
Lymph node 0.85 0.84 0.84
Organ 0.38 0.55 0.50
Note.—Data are  values. The agreement with  values was as follows: 0–0.20, very poor;
0.21–0.40, poor; 0.41–0.60, fair; 0.61–0.80, good; and 0.81–1.00, excellent.
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mance of both imaging modalities was
not different in the assignment of dis-
ease. PET/CT seems to perform better in
exclusion of disease, which represents a
higher diagnostic confidence to exclude
initial disease or recurrence.
A limitation of PET is that small lesions
can be missed. In one patient, the thick-
ening of a small-bowel loop indicated
lymphoma involvement on contrast-en-
hanced CT images. This lesion was not
visible on FDG PET images. Correct inter-
pretation of abdominal FDG uptake can
be difficult, because FDG uptake can be
physiologically increased in small and
large bowel (18).
PET/CT had a greater effect on thera-
peutic decision making in our patients
with Hodgkin disease and high-grade
non-Hodgkin lymphoma than did con-
ventional contrast-enhanced CT. In nine
patients, PET/CT revealed relevant addi-
tional lesions in lymph nodes and organs
at staging and restaging examinations. In
contrast, only in two patients did con-
trast-enhanced CT reveal additional le-
sions, and this revelation led to a change
of clinical management. In one of these
two patients, a mediastinal mass was
identified on a contrast-enhanced CT
scan but was not reported with PET/CT,
although retrospectively this mass was
clearly identified on the nonenhanced
CT image at PET/CT. This case illustrates
the importance of careful interpretation
of the nonenhanced CT scan indepen-
dent from information of the PET scan.
An essential advantage of PET/CT im-
aging over PET imaging alone is the abil-
ity to use CT data for attenuation cor-
rection of emission data in the
reconstruction of PET images. This allows
reduction of total data acquisition time
to less than 25 minutes per patient (19).
If necessary, after completion of scan-
ning, contrast-enhanced CT can be per-
formed in any desired location and can
be used for image fusion. However, our
data suggest that PET/CT performed with
low-dose CT and without intravenous
contrast media is sufficient in staging and
restaging of disease in patients with
Hodgkin disease and high-grade non-
Hodgkin lymphoma.
This study had several shortcomings.
Mainly, the retrospective nature of this
study may have introduced a bias in the
data. The patient population was hetero-
geneous and rather small. Furthermore,
the technique of contrast-enhanced CT
was not standardized, since data acquisi-
tion was performed at different institu-
tions. In addition, the time sequence of
PET/CT and contrast-enhanced CT data
acquisition was not randomized, and
nonstandardized written reports as the
basis of analysis could have reduced the
clinical importance of our results. Our
standard of reference included clinical
patient follow-up information obtained
at biopsy, from clinical and/or laboratory
reports, and at imaging with other tech-
niques. Only a few patients had histo-
logic verification of the specific suspected
pathologic findings. This is a known lim-
itation from previous studies in which
the performance of imaging methods was
compared in lymphoma patients. How-
ever, the aim of this study was to deter-
mine whether the two selected imaging
modalities were able to depict viable tu-
mor tissue and to give correct informa-
tion for staging and restaging, thus rep-
resenting the setting in clinical routine.
Overall, the sensitivity and specificity
for lymph node and organ infiltration of
non-Hodgkin lymphoma and Hodgkin
disease analyzed on a per-patient basis
were better for PET/CT compared with
contrast-enhanced CT. The agreement of
both methods was excellent in regard to
the status of disease of lymph nodes ( 
0.84) but only fair for extranodal disease
(  0.50). A significant difference was
found in regard to exclusion of disease
with PET/CT compared with contrast-en-
hanced CT. Because of identified short-
comings, future prospective studies are
needed for evaluation of the role of
PET/CT in the diagnostic work-up and
treatment of patients with Hodgkin dis-
ease and high-grade non-Hodgkin lym-
phoma.
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